We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

114 hedge funds and large institutions have $423M invested in Concert Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 37 increasing their positions, 23 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

327% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 11

93% more capital invested

Capital invested by funds: $219M → $423M (+$204M)

61% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 23

59% more call options, than puts

Call options by funds: $1.22M | Put options by funds: $769K

44% more funds holding

Funds holding: 79 → 114 (+35)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
114
Holders Change
+35
Holders Change %
+44.3%
% of All Funds
2.59%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
47
Increased
37
Reduced
23
Closed
11
Calls
$1.22M
Puts
$769K
Net Calls
+$452K
Net Calls Change
+$80K

Top Buyers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
+$14.3M
2
BlackRock
BlackRock
New York
+$13.1M
3
Millennium Management
Millennium Management
New York
+$10.1M
4
BC
Boxer Capital
California
+$8.05M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$6M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$26.9M
2
BI
BVF Inc
California
-$23.5M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$5.43M
4
LSC
Lyon Street Capital
California
-$5.21M
5
SM
Senvest Management
New York
-$4.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$4.09M +$3.18M +158,066 New
Two Sigma Investments
27
Two Sigma Investments
New York
$3.93M +$3.06M +151,875 New
MCM
28
Matarin Capital Management
New York
$3.83M +$2.98M +148,213 New
PP
29
PDT Partners
New York
$3.72M +$1.7M +84,310 +142%
TA
30
Teachers Advisors
New York
$3.5M +$2.03M +101,026 +294%
Allianz Asset Management
31
Allianz Asset Management
Germany
$3.01M -$54.6K -2,710 -2%
Arrowstreet Capital
32
Arrowstreet Capital
Massachusetts
$2.81M +$2.19M +108,700 New
D.E. Shaw & Co
33
D.E. Shaw & Co
New York
$2.67M -$4M -198,419 -66%
DCM
34
Driehaus Capital Management
Illinois
$2.59M -$3.27M -162,569 -62%
Connor, Clark & Lunn Investment Management (CC&L)
35
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.58M +$2M +99,525 New
Goldman Sachs
36
Goldman Sachs
New York
$2.56M +$1.31M +65,086 +193%
Wells Fargo
37
Wells Fargo
California
$2.53M +$1.68M +83,388 +576%
QI
38
QS Investors
New York
$2.29M -$51.5K -2,557 -3%
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$2.2M – – –
SM
40
Senvest Management
New York
$1.94M -$4.82M -239,587 -76%
Fisher Asset Management
41
Fisher Asset Management
Washington
$1.94M – – –
Citadel Advisors
42
Citadel Advisors
Florida
$1.81M -$1.1M -54,718 -44%
GCP
43
GSA Capital Partners
United Kingdom
$1.79M +$1.4M +69,300 New
Bank of America
44
Bank of America
North Carolina
$1.72M +$370K +18,396 +38%
Deutsche Bank
45
Deutsche Bank
Germany
$1.66M +$871K +43,269 +206%
DTL
46
Dynamic Technology Lab
Singapore
$1.66M +$1.29M +63,974 New
Two Sigma Advisers
47
Two Sigma Advisers
New York
$1.5M +$1.16M +57,838 New
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$1.35M +$1.05M +52,232 New
Prudential Financial
49
Prudential Financial
New Jersey
$1.33M -$271K -13,467 -21%
DMK
50
David M. Knott
$1.28M +$91.8K +4,557 +10%
1
2
3 4 5

CNCE Hedge Fund Activity: Q4 2017 in Review

114 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2017, worth a combined $423M — up 93% from $219M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new CNCE positions and 11 closed out — a net gain of 36 holders — while 37 added to existing stakes and 23 trimmed.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $14.3M. The largest seller was Great Point Partners, cutting an estimated $26.9M.

  • 114 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2017, up from 79 in Q3 2017.
  • Funds reported $423M of Concert Pharmaceuticals, Inc. stock for Q4 2017, up 93% quarter-over-quarter.
  • 47 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2017 and 11 closed out, a net change of +36 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q4 2017 was Laurion Capital Management, an estimated $14.3M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q4 2017 was Great Point Partners, an estimated $26.9M sold.

Based on aggregated 13F filings for Q4 2017.